Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Taxotere · 2 trials · 2 indications
Patient preference (Taxotere versus Jevtana) assessed by a single question after completion of the second period of chemotherapy. Primary outcome measure will be assessed in the intent-to-treat population as defined by all patients having completed the first 4 cycles without progression and having received at least 1 cycle of the second treatment period. Patients having progressed during the first period will discontinue the trial.
Subjects once off treatment wil be followed for survival
| Arm | Type | Description |
|---|---|---|
| Do/Ca | OTHER | Arm Do/Ca : Taxotere 75mg/m2/3w x 4 cycles, followed by Jevtana 25mg/m2/3w x 4 cycles |
| Ca/Do | OTHER | Arm Ca/Do : Jevtana 25mg/m2/3w x 4 cycles, followed by Taxotere 75mg/m2/3w x 4 cycles |
| Oxaliplatin and Taxotere | EXPERIMENTAL | Patients will receive both docetaxel and oxaliplatin, IV on day 1 of each cycle. Treatment will be repeated every 21 days for up to 6 courses in the absence of disease progression, unacceptable toxicity, or \>50% increase in serum PSA. |
| Name | Type | Description |
|---|---|---|
| Taxotere | DRUG | - |
| Jevtana | DRUG | - |
| Oxaliplatin | DRUG | - |
Inclusion Criteria: * Affiliated to a social security regimen ; * Male patients older than 18 years ; * Histologically confirmed adenocarcinoma of the prostate ; * Continued androgen deprivation therapy either by LHRH agonists/antagonists or orchidectomy ; * Serum testosterone \<0.50 ng/ml (1.7 nmo...
Taxotere is a small molecule oncology drug being studied for prostate cancer, including metastatic castration-resistant prostate cancer. It is developed by Sanofi. Taxotere is currently in Phase 3 clinical development for these indications, meaning it is investigational and not yet approved for this use.
Taxotere is a small molecule drug developed by Sanofi for prostate cancer and metastatic castration-resistant prostate cancer. Its specific molecular target is not disclosed in the available information, so its mechanism of action is not detailed here.
Taxotere is developed by Sanofi, a company listed on the stock exchange under the ticker SNY. Sanofi is conducting clinical trials to evaluate Taxotere for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer.
Taxotere is in Phase 3 clinical development for prostate cancer and metastatic castration-resistant prostate cancer. It is an investigational drug, meaning it has not been approved by regulatory authorities for these indications. Sanofi is the developer of Taxotere.
Taxotere has been studied in clinical trials for prostate cancer. One completed Phase 3 trial, NCT02044354, enrolled 195 patients with metastatic castration-resistant prostate cancer in France. Another completed Phase 2 trial, NCT00260611, enrolled 34 patients with prostate cancer in the United States.
Taxotere is the brand name for docetaxel, a chemotherapy drug. In clinical trials, Taxotere is compared with cabazitaxel, another taxane, to assess patient preference in metastatic castration-resistant prostate cancer. Taxotere is developed by Sanofi and is in Phase 3 development for prostate cancer.